sub:assertion {
  d:DB01105 v:identifier "DB01105" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB01105" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB01105> ;
    dv:drugbank-id "APRD00456" , "DB01105" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:28:20.92> ;
    dv:x-atc <http://bio2rdf.org/atc:A08AA10> ;
    dv:x-cas <http://bio2rdf.org/cas:106650-56-0> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:5021> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2243164> ;
    dv:x-gtp <http://bio2rdf.org/gtp:2586> ;
    dv:x-iuphar <http://bio2rdf.org/iuphar:2586> ;
    dv:x-kegg <http://bio2rdf.org/kegg:C07247> , <http://bio2rdf.org/kegg:D08513> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0074-2456-12> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA451344> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:5210> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46507740> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Sibutramine> ;
    dct:description "Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines. Sibutramine is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease."@en ;
    dct:identifier "drugbank:DB01105" ;
    dct:title "Sibutramine"@en ;
    a dv:Drug ;
    rdfs:label "Sibutramine [drugbank:DB01105]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB01105> , <http://www.drugs.com/cdi/sibutramine.html> , <http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mer1254.shtml> , <http://www.rxlist.com/cgi/generic/sibutramine.htm> .
}